pharmaphorum November 8, 2023
Phil Taylor

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.

Already a blockbuster as a therapy for type 2 diabetes under the Mounjaro brand name, dual GLP-1/GIP agonist tirzepatide has been cleared for obesity as Zepbound, paving the way for a big increase in sales and setting up a battle for market share with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide).

The FDA has approved Zepbound for chronic weight management in adults who are obese with a body mass index of 30 or more, or overweight with a BMI of at least 27 and at least one weight-related health condition, such...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Pharmacy Benefit Manager Reform Keeps Getting Scuttled, Despite Bipartisan Support
AI, patient data firms aim to speed up drug development
HHS files brief in 340B rebate model case: 4 takeaways
The Holy Grail of Biology
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients

Share This Article